Financials

v2.4.0.8
Consolidated Balance Sheets (USD $)
Sep. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 7,877,432 $ 10,048,466
Short-term investments 1,269,467 305,538
Accounts receivable 175,191 458,391
Other current assets 365,461 344,386
Total current assets 9,687,551 11,156,781
Equipment, net 287,827 457,912
Restricted cash 2,427,874 2,921,724
Other long-term assets 65,192 159,224
Total assets 12,468,444 14,695,641
Current liabilities:    
Accounts payable 889,402 794,397
Accrued expenses 1,796,382 2,445,446
Deferred revenue 356,580 1,069,438
Accrued warrant liability 1,861,013 1,241,311
Current portion of notes payable 735,654 351,527
Current portion of capital lease obligation 29,560 83,634
Total current liabilities 5,668,591 5,985,753
Noncurrent portion of capital lease obligation   7,522
Long-term debt 3,479,396 7,121,388
Commitments and contingencies      
Total liabilities 9,147,987 13,114,663
Stockholders' equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively      
Common stock, $.005 par value; 160,000,000 shares authorized, 57,110,198 and 45,182,114 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively 285,551 225,911
Additional paid-in capital 134,773,438 125,508,471
Other comprehensive income/(loss) (201,214) 307,339
Accumulated deficit (145,207,333) (135,564,666)
Total Cleveland BioLabs, Inc. stockholders' deficit (10,349,558) (9,522,945)
Noncontrolling interest in stockholders' equity 13,670,015 11,103,923
Total stockholders' equity 3,320,457 1,580,978
Total liabilities and stockholders' equity $ 12,468,444 $ 14,695,641
v2.4.0.8
Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Revenues:        
Grants and contracts $ 415,126 $ 1,635,600 $ 2,311,467 $ 4,616,334
Operating expenses:        
Research and development 2,068,245 4,205,238 6,832,241 14,909,882
General and administrative 1,785,620 3,286,830 6,449,531 9,787,053
Total operating expenses 3,853,865 7,492,068 13,281,772 24,696,935
Loss from operations (3,438,739) (5,856,468) (10,970,305) (20,080,601)
Other income (expense):        
Interest and other income (expense) (68,932) 97,534 (1,010,640) 225,299
Foreign exchange gain (loss) (271,699) (15,057) (330,876) 59,853
Change in value of warrant liability (836,293) 1,163,030 1,663,390 510,919
Total other income (expense) (1,176,924) 1,245,507 321,874 796,071
Net loss (4,615,663) (4,610,961) (10,648,431) (19,284,530)
Net loss (4,615,663) (4,610,961) (10,648,431) (19,284,530)
Net loss attributable to noncontrolling interests 519,529 519,765 1,005,764 2,386,900
Net loss attributable to Cleveland BioLabs, Inc. $ (4,096,134) $ (4,091,196) $ (9,642,667) $ (16,897,630)
Net loss available to common stockholders per share of common stock, basic and diluted $ (0.07) $ (0.09) $ (0.18) $ (0.38)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted 57,110,198 45,061,274 53,016,147 44,946,340
v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net loss $ (10,648,431) $ (19,284,530)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 154,602 284,278
Amortization 609,837  
Loss on equipment disposal 24,685  
Noncash compensation 252,651 1,591,986
Warrant issuance costs 171,116  
Change in value of warrant liability (1,663,390) (510,919)
Changes in operating assets and liabilities:    
Accounts receivable 361,391 (565,336)
Other current assets (74,659) 452,798
Other long-term assets 19,592 (3,995)
Accounts payable 132,499 (310,150)
Deferred revenue (588,759) (1,102,472)
Accrued expenses (67,699) 525,198
Net cash used in operating activities (11,316,565) (18,923,142)
Cash flows from investing activities:    
Purchase of short-term investments (1,412,916)  
Sale of short-term investments 282,583 2,213,999
Purchase of equipment (12,328) (125,218)
Increase in restricted cash   (1,421,861)
Net cash provided by (used in) investing activities (1,142,661) 666,920
Cash flows from financing activities:    
Issuance of common stock, net of offering costs 9,697,501  
Net proceeds/(repayment) of long-term debt (4,000,000) 7,297,675
Noncontrolling interest capital contribution to Incuron, LLC 5,152,393  
Exercise of options   12,392
Repayment of capital lease obligation (61,596) (59,012)
Net cash provided by financing activities 10,788,298 7,251,055
Effect of exchange rate change on cash and equivalents (500,106) (333,995)
Decrease in cash and cash equivalents (2,171,034) (11,339,162)
Cash and cash equivalents at beginning of period 10,048,466 25,652,083
Cash and cash equivalents at end of period 7,877,432 14,312,921
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 415,621 17,105
Supplemental schedule of noncash financing activities:    
Noncash financing costs on common stock offering 50,505  
Noncash warrant issuance costs $ 15,993 $ 117,999
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue